Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$49 Mln
P/E Ratio
--
P/B Ratio
0.44
Industry P/E
--
Debt to Equity
--
ROE
-0.45 %
ROCE
-41.02 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-451.85 Mln
EBITDA
$-619.52 Mln
Net Profit
$-623.68 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Allovir Inc (ALVR)
| 2,235.71 | -0.91 | 2,046.61 | 1,159.47 | 5.23 | -- | -- |
|
BSE Sensex*
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Allovir Inc (ALVR)
| -37.99 | -86.74 | -60.36 | -66.34 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.14 | 10,135.98 | 20.78 | 23.13 | |
| 294.39 | 8,668.61 | 21.55 | 58.42 | |
| 27.74 | 9,559.25 | -- | -28.77 | |
| 106.10 | 10,030.35 | 30.81 | 14.16 |
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead... product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts. Address: 1100 Winter Street, Waltham, MA, United States, 02451 Read more
Executive Chairman of the Board
Mr. David L. Hallal
Executive Chairman of the Board
Mr. David L. Hallal
Headquarters
Waltham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Allovir Inc (ALVR) stood at $ 119 Mln as on 31-Dec-24
The share price of Allovir Inc (ALVR) is $9.81 (NASDAQ) as of 18-Mar-2025 16:00 EDT. Allovir Inc (ALVR) has given a return of 5.23% in the last 3 years.
Allovir Inc (ALVR) has a market capitalisation of $ 49 Mln as on 19-Mar-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Allovir Inc (ALVR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Allovir Inc (ALVR) and enter the required number of quantities and click on buy to purchase the shares of Allovir Inc (ALVR).
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts. Address: 1100 Winter Street, Waltham, MA, United States, 02451
The CEO & director of Mr. David L. Hallal. is Allovir Inc (ALVR), and CFO & Sr. VP is Mr. David L. Hallal.
There is no promoter pledging in Allovir Inc (ALVR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Allovir Inc (ALVR) | Ratios |
|---|---|
|
Return on equity(%)
|
-45.37
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Allovir Inc (ALVR) was $0 Mln.
$0.15
(
